87 completed, 38 recruiting, 26 terminated, 17 unknown. 200 Phase 2, 49 Phase 1, 23 Phase 3.
Follow Scleroderma, Systemic: new trials by email Literature Review of Scleroderma, Systemic trials Research Report on Scleroderma, Systemic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital Ulcers L608, Placebo - Systemic Sclerosis | Phase 2 | Not yet recruiting | Pharmosa Biopharm Inc. | 40 | 2027-02-01 | 2026-11-09 |
| An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1 CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Not yet recruiting | University Hospital Tuebingen | 36 | 2027-01-01 | 2026-11-12 |
| A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further. ABBV-722, Upadacitinib, Placebo for ABBV-722 - Systemic Sclerosis | Phase 2 / Phase 3 | Not yet recruiting | AbbVie | 580 | 2026-12-11 | 2026-11-12 |
| Mycophenolate After Stem Cell Transplant for Systemic Sclerosis Mycophenolate Mofetil 1000 mg twice daily - Systemic Sclerosis (SSc) | Phase 2 | Not yet recruiting | Ottawa Hospital Research Institute | 6 | 2026-12-01 | 2026-10-19 |
| Hyaluronidase Injections for Sclerodactyly in Patients With Scleroderma hyaluronidase - Scleroderma, Sclerodactyly | Phase 2 | Not yet recruiting | Stanford University | 10 | 2026-12-01 | 2026-11-06 |
| A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases PF-08154225 - Systemic Lupus Erythematosus, Rheumatoid Arthritis | Phase 1 / Phase 2 | Not yet recruiting | Pfizer | 54 | 2026-11-19 | 2026-10-01 |
| Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Peking University Third Hospital | 9 | 2026-11-01 | 2026-09-23 |
| Hyperpolarized Xenon MRI in Adults With Pulmonary Hypertension in Interstitial Lung Disease and Systemic Sclerosis Hyperpolarized 129 Xenon Gas - Interstitial Lung Disease, Pulmonary Hypertension | Phase 2 | Not yet recruiting | Bastiaan Driehuys | 51 | 2026-11-01 | 2026-09-15 |
| Obinutuzumab in Systemic Sclerosis Obinutuzumab, Placebo - Systemic Sclerosis in Adults | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 120 | 2026-11-01 | 2026-09-25 |
| FAPI PET in Systemic Sclerosis Interstitial Lung Disease FAPI tracer - Systemic Sclerosis (SSc), Scleroderma | Phase 2 | Not yet recruiting | University of California, Los Angeles | 120 | 2026-11-01 | 2026-11-12 |
| A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks LIQ861 (treprostinil) inhalation powder - Dose Titration Arm, LIQ861 (treprostinil) inhalation powder - fixed dose arm - Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Not yet recruiting | Liquidia Technologies, Inc. | 75 | 2026-10-26 | 2026-08-07 |
| Rituximab vs Placebo for Maintenance in Systemic Sclerosis - Interstitial Lung Disease Rituximab, Placebo - Systemic Sclerosis in Adults | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 120 | 2026-10-01 | 2026-09-18 |
| FT839 in Autoimmune Diseases FT839 - ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | Phase 1 / Phase 2 | Recruiting | Fate Therapeutics | 446 | 2026-10-01 | 2026-09-02 |
| Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis 10 mg/kg CM-101, Placebo - Systemic Sclerosis | Phase 2 | Suspended | ChemomAb Ltd. | 45 | 2026-09-01 | 2026-04-15 |
| A Study to Test CRT-402 in Refractory Autoimmune Disease CRT-402 - Autoimmune Diseases, Systemic Lupus Erythematosus | Phase 1 / Phase 2 | Recruiting | Myeloid Therapeutics | 34 | 2026-08-26 | 2026-10-22 |
| A Phase II Study of TollB-001 Tablets in Systemic Sclerosis TollB-001 Tablet, Placebo - Systemic Sclerosis (SSc) | Phase 2 | Not yet recruiting | Toll Biotech Co. Ltd. (Beijing) | 36 | 2026-08-01 | 2026-08-04 |
| Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy CD19 CAR T Arm - Scleroderma, Systemic | Phase 2 | Recruiting | University Hospital, Montpellier | 6 | 2026-06-11 | 2026-10-14 |
| EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc) MTX-474, Placebo - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Recruiting | Mediar Therapeutics | 85 | 2026-04-16 | 2026-10-05 |
| Controlling Hyperactive Immunity With Long-lived Lymphocytes QEL-005 - Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA) | Phase 1 / Phase 2 | Recruiting | Quell Therapeutics Limited | 16 | 2026-04-10 | 2026-10-19 |
| Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Systemic Sclerosis HS_SW01 cells injection - Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Huishan Biotechnology Co., Ltd. | 21 | 2026-04-10 | 2026-04-21 |
Showing 20 of 200. Sign in to see all of them.
Scleroderma, Diffuse (92) · Lung Diseases, Interstitial (22) · Raynaud Disease (15) · Lupus Erythematosus, Systemic (14) · Arthritis, Rheumatoid (13) · Autoimmune Diseases (13) · Myositis (11) · Connective Tissue Diseases (9) · Dermatomyositis (9) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (8) · digital ulcers (8) · Hypertension, Pulmonary (7) · Pulmonary Fibrosis (7) · Sjogren's Syndrome (7)
Skin and Connective Tissue Diseases (200) · Skin Diseases (193) · Connective Tissue Diseases (191) · Lung Diseases (35) · Respiratory Tract Diseases (35) · Cardiovascular Diseases (34) · Immune System Diseases (32) · Vascular Diseases (32) · Musculoskeletal Diseases (26) · Pathological Conditions, Signs and Symptoms (26) · Skin Diseases, Vascular (24) · Joint Diseases (20) · Pathologic Processes (20) · Autoimmune Diseases (19)
Mycophenolic Acid (13) · Cyclophosphamide (11) · Rituximab (11) · Imatinib Mesylate (8) · Bosentan (5) · Antilymphocyte Serum (4) · fludarabine phosphate (4) · treprostinil (4) · Brentuximab Vedotin (3) · Filgrastim (3) · Immunoglobulins, Intravenous (3) · Methylprednisolone (3) · Sildenafil Citrate (3) · Whole-Body Irradiation (3) · belimumab (3)
Assistance Publique - Hôpitaux de Paris (7) · Hospital for Special Surgery, New York (4) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (4) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Novartis Pharmaceuticals (4) · Stanford University (4) · Actelion (3) · Fred Hutchinson Cancer Center (3) · Northwestern University (3) · Pfizer (3) · University College, London (3) · University Hospital, Grenoble (3) · University of California, Los Angeles (3) · University of Michigan (3) · Amgen (2)
United States (97) · United Kingdom (42) · France (34) · Germany (32) · Italy (30) · Spain (24) · Canada (22) · Poland (21) · Australia (15) · Belgium (14) · China (14) · Switzerland (14) · Mexico (13) · Argentina (11) · Netherlands (11)
Robert Spiera, MD (4) · Ayumi Yoshizaki, MD, PhD (2) · Daniel E. Furst, MD (2) · Dinesh Khanna, MD (2) · George Georges (2) · James Seibold, MD (2) · Leona Holmberg (2) · Richard Burt, MD (2)
PMID 28298564, PMID 35904231, PMID 41217519, PMID 11934971, PMID 15692967, PMID 15942915, PMID 16790698, PMID 17469162, PMID 17485423, PMID 17717203, PMID 17901414, PMID 18512816, PMID 18634152, PMID 18641099, PMID 19103636, PMID 19180499, PMID 19776222, PMID 19892673, PMID 19950289, PMID 20506355, PMID 20708086, PMID 20740615, PMID 20800376, PMID 21398330, PMID 21769849, PMID 21777972, PMID 22227955, PMID 22542159, PMID 23039171, PMID 23118116, PMID 23402088, PMID 23418384, PMID 23494072, PMID 23554239, PMID 24054756, PMID 24067785, PMID 24459219, PMID 24489014, PMID 24850877, PMID 25007944, PMID 25452309, PMID 25826322, PMID 26071192, PMID 26283632, PMID 26378033, PMID 26724322, PMID 27134280, PMID 27370878, PMID 27463733, PMID 27469583
2019 (6), 2023 (4), 2025 (4), 2014 (3), 2015 (2), 2016 (2), 2018 (2), P30CA015704 (2), 1UM1AI110557 (1), 2005 (1), 2008 (1), P50AR080612 (1), R01AI041721 (1), R01AR047219 (1), R01HL089758 (1)